CGS vs EYE

ASX Healthcare sector comparison — updated 14 Jul 2026 — Healthcare sector

CGS

COGSTATE FPO [CGS]

58MEDIUM

EYE

NOVA EYE FPO [EYE]

57MEDIUM

Score Breakdown

CGS EYE
Technical
47
57
Catalyst
53
53
Sentiment
50
50
Fundamental
96
76
Momentum
79
39
Risk Gate
50
45

Key Metrics

CGS Metric EYE
$489.3MMarket Cap$32.8M
397KAvg Volume (20d)269K
+0.1%Short InterestN/A
$3.01052-Week High$0.205
$1.55052-Week Low$0.100
-3.5%Daily Change+0.0%
$2.780Reference Price$0.115
+22.5%ROE-42.4%
+19.2%Profit Margin-21.3%

Active Signals

CGS Signals

●MACD crossed bearish — momentum is fading
●Volume surging at 2.4x normal while price falls — heavy selling pressure
●Trading above the 200-day average — the long-term trend is on your side
●Cash positive / operating cashflow positive
●Moderate P/S ratio (8.7x)
●Moderate revenue growth (+12%)
●Piotroski F-Score strong (8/9, low-confidence approx)
●EPS estimates revised upward (+10pts)

EYE Signals

●MACD momentum is picking up steam
●Stochastic is stretched into overbought — could need a breather
●Volatility is contracting — like a spring being compressed, breakouts often follow
●Below the 200-day average — the long-term trend is still working against it
●Low cash runway (2 quarters) - dilution risk
●Low P/S ratio (1.0x)
●Strong revenue growth (+29%)
●EPS estimates revised upward (+10pts)

Ask Scout AI to compare CGS and EYE in depth.

Open Scout AI →

Track both stocks and 2,200+ more — Free

Daily AI-powered screening across every ASX small cap.

Open Screener

Related Comparisons

CGS vs MVP →AHC vs CMP →AHC vs ARX →AHC vs EYE →ARX vs CMP →
CGS Full Analysis → EYE Full Analysis → Healthcare Sector → All Comparisons →
GENERAL INFORMATION ONLY. SmallCapData provides algorithmic screening data and does not constitute personal financial advice, a recommendation, or an offer to buy or sell any security. This content is produced by an algorithm, not a licensed financial adviser. You should consider seeking independent financial advice before making any investment decision. Past performance is not indicative of future results. Trading in small-cap securities carries a high degree of risk, including the risk of total loss of capital. The author may hold positions in mentioned securities. SmallCapData does not hold an Australian Financial Services Licence (AFSL).